GlassScriptPhysician profile
Michael D Delange
NPI 1043390958
$4,221.22
in general payments reported to CMS, 2019-2025
43 companies · $940 in 2025
The $940 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $546 · 2023: $796 · 2024: $727 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.28 | 2019-2025 | Farxiga |
| Abbvie INC. | $367.92 | 2023-2025 | Vraylar, Liletta |
| Novo Nordisk INC | $322.12 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $295.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $257.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $240.06 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $185.79 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $182.19 | 2019-2025 | Gardasil 9, Capvaxive, Rotateq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.59 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.55 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $128.39 | 2019-2024 | Spravato, Xarelto |
| Allergan, INC. | $126.08 | 2019-2020 | |
| Amgen INC. | $119.83 | 2019-2024 | Repatha, Tavneos, Otezla |
| E.R. Squibb & Sons, L.L.C. | $108.74 | 2019-2020 | |
| Axsome Therapeutics, INC. | $99.93 | 2023-2025 | Auvelity, Sunosi |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Delange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.